Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAUTILUS: Bocodepsin + Binimetinib in Advanced Solid Tumors and Melanoma
NCT05340621Phase 2Completed
- Sponsor
- OnKure Therapeutics
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bocodepsin in solid tumor and melanoma, sponsored by OnKure Therapeutics. Primary endpoints: Incidence and severity of dose-limiting toxicities, Incidence and severity of adverse events at 1.5 years and 3 more. Started May 2022; status: completed.
02
Drugs
bocodepsin
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT05340621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340621.